Zacks: Analysts Anticipate Zynex Inc. (NYSE:ZYXI) Will Post Quarterly Sales of $11.06 Million

Analysts expect that Zynex Inc. (NYSE:ZYXI) will announce sales of $11.06 million for the current quarter, Zacks reports. Two analysts have provided estimates for Zynex’s earnings, with estimates ranging from $11.00 million to $11.12 million. Zynex reported sales of $8.13 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 36%. The company is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Zynex will report full-year sales of $43.17 million for the current fiscal year, with estimates ranging from $43.00 million to $43.35 million. For the next year, analysts anticipate that the firm will post sales of $57.36 million, with estimates ranging from $56.28 million to $58.45 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Zynex.

Zynex (NYSE:ZYXI) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.06. The firm had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $9.84 million.

ZYXI has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating on shares of Zynex in a research report on Monday, September 23rd. B. Riley reissued a “buy” rating on shares of Zynex in a research report on Tuesday, October 15th.

NYSE:ZYXI opened at $10.48 on Friday. Zynex has a 1-year low of $2.58 and a 1-year high of $13.10.

About Zynex

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device.

Recommended Story: Cryptocurrencies

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.